KalVista Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical needs, particularly hereditary angioedema (HAE). Its lead product, EKTERLY (sebetralstat), is an FDA-approved oral on-demand plasma kallikrein inhibitor designed to treat acute HAE attacks, offering a convenient alternative to injectable therapies by enabling rapid symptom relief when taken at the onset of an attack. The company is also advancing other oral formulations, including an orally disintegrating tablet version called KONFIDENT-KID tailored for pediatric patients, and a preclinical Factor XIIa inhibitor, both targeting HAE to expand treatment options across age groups. KalVista Pharmaceuticals Inc. operates in the rare disease space, emphasizing patient-centric innovations that improve treatment adherence and satisfaction through non-invasive delivery. With regulatory approvals in multiple markets and partnerships for international expansion, it plays a key role in transforming on-demand HAE management by prioritizing oral therapies that address limitations of existing standards.